PharmedOut Fodder
Each month, the PharmedOut Newsletter covers a pressing issue on industry's influence on the medical world. You can read all of the fodders on this page.
2024
March 2024: Proposed bill on off-label promotion gets pulled
February 2024: Painful Presentation: KOL gives problematic lecture on opioids
2023
December 2023: Rexulti ads: both depressing and agitating
October 2023: Pharma-funded groups pressure Medicare to cover obesity drugs
September 2023: Is the Alzheimer's Association guiding patients to an early grave?
August 2023: Who's really behind the weight loss drug hype?
June & July 2023: Why we're salty with Jazz Pharmaceuticals and the AHA
May 2023: Why are opioids approved for chronic pain when they don’t work?
April 2023: Breathtaking Unbranded Marketing from Amgen
March 2023: Novo Nordisk outed for veiled marketing through third parties
February 2023: Bite-sized sponsored education is still advertising
January 2023: Overweight and Over Wegovy
2022
December 2022: Pharma's Payout to Nurse Practitioners and Physician Assistants
November 2022: Selling drugs and patients' bodies
October 2022: Health Union? More like, Stealth Union
September 2022: Does $500,000 a year for a drug make your eyes bulge? We have a drug for that...
August 2022: Will California's opioid guidelines cave to industry pressure?
July 2022: "Have your cake and eat it too": wood pulp for weight loss
June 2022: Quivering with Quviviq: New sleep drug uses the same old marketing playbook
May 2022: McKinsey & Company: Double Agent for Purdue and FDA
March 2022: Let's lose the term "legitimate pain patient"
February 2022: "It's a trap!" A doctor and a patient duped by Pharma speak out
2021
November 2021: Sales of Some Opioids Lift Sales of All Opioids
October 2021: The FDA Should Mandate Industry-free CME
September 2021: Manufacturing Doubt and Evading Responsibility
July 2021: What Does a "Human Rights" Frame for Pain Advocacy Look Like?
May/June 2021: Another Key Player in Purdue's Opioid Marketing Strategy
April 2021: New and Convenient Does Not Equal Better and Safe
March 2021: Opioid Marketing Tactics: The Old and the New
February 2021: Why is the AMA Promoting Opioid Use?
January 2021: The House and the Senate Take on Opioid Marketing
2020
December 2020: McKinsey Proposed What to Purdue?
November 2020: Purdue's Most Successful Strategy No One Is Talking About
October 2020: Industry's Influence on Pain Patients' Advocacy
September 2020: The UK's Take on the Treatment of Chronic Primary Pain
August 2020: Yet Another Industry-Friendly Platform for Opioid Promotion
July 2020: Will the CDC Opioid Guideline Update be Informed by Scientific Evidence or Narrative?
June 2020: Asking About Pain Tolerance Could Lead to Fewer Opioid Prescriptions
May 2020: Triplicate States and Opioid Prescribing
April 2020: Fact or Fiction? How Opioid Misinformation Continues Online
March 2020: We Know About Opioids, but Where Else Are Pharma Payments Going?
February 2020: The Trouble with Tramadol
January 2020: Story vs. Anti-Story in Opioid Marketing
2019
December 2019: In Opioid Cases, Look to Tobacco Litigation for Guidance
November 2019: When Sunshine Doesn't Cast Enough Light
October 2019: Disinfecting Pharma with Sunshine: The Case for Bringing Documents to Light
September/August 2019: Highlights from the Johnson & Johnson Opioids Verdict
May 2019: Preventing a new generation of opioid “legacy patients”
April 2019: Who's Really Advocating for Pain Patients?
March 2019: Industry's Voice, Pain Patient's Face
February 2019: What Really Helps Chronic Pain Patients?
2018
December 2018: An opioid treatment for depression nixed by FDA advisory committee
November 2018: Make Punishment Personal
October 2018: Greater Decline in Opioid Prescribing After CDC Guidelines Released
August 2018: A Million Ways to Market a Pill
July 2018: Subsys Sales, from Salacious to Scammy
May 2018: Pharma and the NIH: Innocence by Association?
April 2018: Purdue's Latest PR Move
March 2018: Rx Files: No Medication is Benign, Part 2
February 2018: Rx Files
January 2018: PharmedOut Review in Photos
2017
December 2017: Final Nail in the Addyi Coffin?
November 2017: Joy's Favorite Article of the Month
October 2017: Live from capitol hill: McCaskill investigates Insys marketing practices
September 2017: Rx Files
August 2017: Rx Files
June 2017: When it comes to drug allergies: Time is money
April 2017: Orphan Drugs: Pharma's New Favorite Child
March 2017: Does Industry Influence Medical Discourse?
February 2017: Rx Files
January 2017: Live at the FDA
2016
December 2016: Rx Files
November 2016: Rx Files
October 2016: FDA Caves to Patient Pressure
September 2016: Rx Files
August 2016: Salespeople in the Surgical Suite
July 2016: Blood Money: Pharma Targets People with Hemophilia
June 2016: Pharma Backed Co-Pay Charities
May 2016: Pharma Should Invest in Take-Back Programs
April 2016: ProPublica Proves Why Lunch, and Other Gifts, Matter
March 2016: Problems With Clinical Trials
February 2016: Pharma's Role in the Opioid Crisis
January 2016: Unethical Trials on Unethically Long Shifts
2015
December 2015: Doctors Speak Out on DTC Advertising
November 2015: Pharma University
October 2015: Making an Example of Martin Shkreli
September 2015: Opioids for Kids
August 2015: Let's Keep Transparency in CME
July 2015: More on the Flibanserin Fight
June 2015: Psychiatry Under the Influence
May 2015: Burning Questions to be Answered at PharmedOut Conference
April 2015: 21st Century Pandering
March 2015: The Real Risks of Rx Drugs
February 2015: Demanding Results of Clinical Trials
January 2015: The Rising Costs of Prescription Drugs
2014
December 2014: There's a (Pharma) App for That
November 2014: Standards for FDA Drug Approval
October 2014: "Where's the Female Viagra?"
September 2014: When Pharma Meets Medical Journals
August 2014: Sunshine Still Misses CME
July 2014: What's in a Word?
June 2014: The Bullying of Journal Editors
May 2014: Transparency
April 2014: Attention Deficit Disorder/ Attention Deficit Hyperactivity Disorder
March 2014: Testosterone and Opioids (A Tie)